DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Clinical Trial of Low-Dose Theophylline and Montelukast in Patients with Poorly Controlled Asthma.

Author(s): Irvin CG, Kaminsky DA, Anthonisen NR, Castro M, Hanania NA, Holbrook JT, Lima JJ, Wise RA

Affiliation(s): University of Vermont School of Medicine, Burlington, VT, USA.

Publication date & source: 2006-09-22, Am J Respir Crit Care Med., [Epub ahead of print]

Background: Asthma treatment guidelines recommend addition of controller medications for patients with poorly controlled asthma. We compared the effectiveness of once-daily oral controller therapy with either an antileukotriene receptor antagonist (montelukast) or low-dose theophylline added to existing medications in patients with poorly-controlled asthma. Methods: We conducted a randomized, double-masked, placebo-controlled trial in 489 participants with poorly controlled asthma randomly assigned to placebo, theophylline (300 mg/day) or montelukast (10 mg/day). Participants were followed for 24 weeks to measure the rate of episodes of poor asthma control (EPACs) defined by: decreased peak flow, increased beta agonist use, oral corticosteroid use or unscheduled health care visits. Observations: There was no significant difference in EPAC rates (events/person - year) compared to placebo: low-dose theophylline 4.9 (95% CI 3.6 - 6.7; NS); montelukast 4.0 (95% CI 3.0 - 5.4; NS) and placebo 4.9 (95% CI 3.8 - 6.4). Both montelukast and theophylline caused small improvements in pre-bronchodilator FEV1 of borderline significance. Nausea was more common with theophylline only during the first four weeks of treatment. Neither treatment improved asthma symptoms or quality of life. However in patients not on inhaled corticosteroids (ICS), addition of low-dose theophylline significantly (p<0.002) improved asthma control and symptoms as well as lung function. Conclusions: Neither montelukast nor low-dose theophylline lowered the event-rate of poor asthma control in patients with poorly-controlled asthma despite improved lung function. For patients not using ICS, low-dose theophylline improved asthma symptom control more than montelukast or placebo and provides a safe and low-cost alternative asthma treatment.

Page last updated: 2006-11-04

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017